The P2X 4 receptor is a newly identified receptor expressed in the heart cell. Its function was elucidated with cardiac transgenic (TG) expression of the receptor by using the myocardiumspecific α-myosin heavy chain promoter. The presence of the transgene was determined by polymerase chain reaction by using primers specific to the receptor and the vector linker region, by Southern blotting of the genomic DNA, and by immunoblotting and immunohistochemistry of both isolated cardiac myocytes and intact hearts. In intact heart study, the P2X 4 receptor TG mouse exhibited significantly elevated basal cardiac contractility with greater rates of contraction and relaxation, left ventricular developed pressure, and cardiac output compared with nontransgenic (NTG) animals but showed no evidence of hypertrophy or heart failure. The TG heart also showed a greater increase of cardiac contractility in response to the P2X receptor agonist 2-methylthioATP, consistent with overexpression of a functional P2X 4 receptor with consequent increase in the receptor-mediated response. In isolated cardiac cell study, the TG heart cell showed a similar level of basal contraction amplitude as the NTG heart cell while exhibiting a threefold greater increase in contractility during stimulation by 2-methylthioATP. Thus, an increased responsiveness of the overexpressed P2X 4 receptor to endogenous ATP is responsible for the enhanced basal cardiac performance in the intact TG heart. The sustained enhanced contractile function with no associated heart pathology in the P2X 4 receptor TG mouse suggests a novel physiologic role of the P2X 4 receptor, that of stimulating the cardiac contractility.
protein-coupled P2Y receptor and the ligand-gated ion channel P2X receptor (7, 8) . In the cardiac cell, ATP stimulates a large increase in the cytosolic calcium transient and myocyte contractile amplitude without an enhanced sensitivity of the myofilament to calcium (9-12; for review, see 13) . In rat and chick cardiac cells (14, 15) , the P2X receptor-selective agonist 2-methylthioATP (2-meSATP) was able to stimulate myocyte contractile amplitude with little or no effect on the phospholipase C activity. This increase in contractile amplitude occurred in the presence of phospholipase C inhibitor U-73122. These data suggest that a cardiac P2X receptor likely mediates the increase in myocyte contractility in response to ATP. The objective of the present study was to determine the potential physiologic role of a specific P2X receptor, the P2X 4 receptor, in the heart. Two approaches were used to elucidate the biological function of this receptor. The first approach compared the functional features of the contractile response mediated by native myocyte P2 receptors with those of the cloned P2X receptor subtypes. The second approach carried out cardiac transgenic (TG) expression of the P2X 4 receptor and showed a novel contractile phenotype.
MATERIALS AND METHODS

Materials
ATP, α,β-methylene ATP, 2-meSATP, and suramin were obtained from Sigma Chemical Co., (St. Louis, MO). Liberase (type 2) was from Roche Molecular Biochemicals (Indianapolis, IN). The α-myosin heavy chain promoter was obtained from J. Robbins (University of Cincinnati), and the full-length cDNA encoding the human P2X 4 receptor was supplied by W. Stumers and F. Soto (Max-Planck Institute for Experimental Medicine, Gottingen, Germany). ECL-Plus kit was from Amersham (Piscataway, NJ). B6SJL/F1 mice were obtained from The Jackson Laboratories (Bar Harbor, ME), and 3-month-old Sprague Dawley rats were obtained from Charles River (Cambridge, MA).
Preparation of cardiac ventricular myocytes and measurement of contractile amplitude
We isolated cardiac cells from 3-month-old nontransgenic (NTG) B6SJL/F1, and P2X 4 transgenic (TG) mice, according to a previously described method (16) . Briefly, after perfusion with Ca 2+ -free modified Tyrode's solution, for 5 min, hearts were treated with liberase (Roche Molecular Biochemicals, Inc.) in 25 µM CaCl 2 -containing modified Tyrode's solution for 7-10 min. The modified Tyrode's solution consisted of (mM) NaCl 126, KCl 4.4, MgCl 2 1.0, NaHCO 3 18, glucose 11, HEPES 4, and BDM (2,3-butanedione monoxime), pH 7.4, and were gassed with 5% CO 2 /95% O 2 . The digested heart was then cut into small pieces and gently agitated and incubated in the 100 µM Ca 2+ -containing modified Tyrode's solution. The cell suspension was sedimented by gravity for 10 min, and the pellet was resuspended in 200 µM Ca
2+
-containing solution and allowed to settle for 15 min at 30ûC. The cells were then resuspended in culture medium containing 5% heat-inactivated fetal bovine serum (Sigma), 47.5% MEM (GIBCO, Great Island, NY), 47.5% modified Tyrode's solution, 10 mM pyruvate, 4 mM HEPES, and a further addition of 6 mM glucose at 30ûC in 5% CO 2 atmosphere until use within 6 h. We isolated adult rat cardiac cells according to a previously described method (15) , except that liberase was used as the digesting enzyme at a concentration of 0.1 mg/ml. Individual mouse cardiac cell was superfused with HEPES-buffered solution containing (mM) NaCl 137, KCl 3.7, MgCl 2 0.5, HEPES 4.0, CaCl 2 1.1, and glucose 5.6, pH 7.4. The contractile amplitude was then quantitated by using an optical video motion detection system as previously described (15) . Cardiac cells, plated on laminin-coated coverslips, were field-stimulated at a rate of 0.5 Hz, with platinum electrodes connected to a voltage stimulator. Light-dark contrast at the edge of the myocyte provided a marker for measurement of the amplitude of motion. Cells were then superfused for 3 min with the same HEPES-buffered solution containing the P2 receptor receptor agonist, and changes in contractile amplitude were determined. ATP concentration in agonist-free buffer superfusing the myocyte was measured by quantitating the relative light intensity following firefly luciferase-catalyzed oxidation of D-luciferin by ATP in a luminometer (17) .
Generation of the P2X 4 receptor transgenic mice
TG construct was generated by subcloning a 1.8-kb Hind III fragment of human P2X 4 cDNA (hP2X 4 ) into Hind III site of α-MyHC (α-myosine heavy chain) expression vector, which was sequenced to confirm its orientation and identity. Following Not I digestion, the recombinant clone, was purified by by Elutip (Qiagen, Valencia, CA) and microinjected into the male pronucleus of the B6SJL/F1 mouse zygote. Injected fertilized oocytes were implanted in the pseudopregnant female mice. Founders and subsequent generations of TG mice were identified by Southern blotting and polymerase chain reaction (PCR) of the genomic DNA.
Immunoblotting and immunohistochemistry
Isolated cardiac cells were solublized in sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer, and 50 µg of solublized proteins resolved by 10% SDS-PAGE, transferred to Nitrocellulose membrane (Schleicher & Schuell, Keene, NH), followed by probing with rabbit polyclonal antibody directed against a unique c-terminus sequence of the rat P2X 4 receptor (Alomone, Jerusalem Israel; 18, 19) , which is 94% homologous to the mouse P2X 4 receptor at the amino acid level; the unique P2X 4 receptor cterminal sequence was 100% identical between the rat and mouse receptors (20) . After several washes, the nitrocellulose membrane was incubated with peroxidase-coupled anti-rabbit Ig antibody (1:5,000) and developed with an ECL-Plus kit (Amersham, Arlington Heights, IL). The same antibody incubated with its peptide antigen was used as negative control.
Immunohistochemistry of isolated cardiac cells and intact heart sections of TG and NTG mice with the P2X 4 receptor antibody was performed according to a previously described method (21) . Mouse heart sections and cardiac cells adherent to laminin-coated coverslips were fixed by 4% paraformaldehyde. After blocking by goat serum in phosphate-buffered saline with 0.1% Tween at room temperature for 30 min, the cell or heart section was incubated with the P2X 4 receptor antibody (1:300 dilution) at 4ûC overnight. The bound antibody was detected with the Vector ABC Alkaline Phosphate kit, and reaction product was visualized with the Vector Red Substrate kit, according to the standard protocol as previously described (21) . In another study, paraffinembedded heart sections from both TG and NTG mice were subjected to Hematoxylin and Eosin staining.
Physiologic measurement in isolated mouse hearts
Various parameters of intact heart function, such as left ventricular developed pressure (LVDP), cardiac output, and rates of contraction and relaxation (±dP/dt), were determined quantitatively by using the working heart model as described previously (15) . The LVDP was the difference between LV systolic and diastolic pressure. The basal heart rate was determined in the absence of pacing. A drug such as 2-meSATP was infused into a side port of a reservoir of buffer that maintained a "venous return" flow into the left atrium via a catheter as previously described (15) . The drug-containing buffer then entered the left ventricle and the coronary circulation after its ejection into the aorta during systole. The duration of circulation of the drug-containing perfusate was ~2-2.5 min, during which the various functional parameters were recorded. The pressure recordings were made by using a fluid-filled system of pressure transducer, channeled from a precalibrated amplifier (Kent Scientific Corp., Litchfield, CT), and the signals were digitized via a PCM-DAS 16S/330 interface board (Computer Boards, Inc., Mansfield, MA). Data were analyzed by computer software (WorkBench for Windows + , Kent Scientific Corp.). The amplified and digitized signals from the transducers were constantly displayed and analyzed. The systolic blood pressure and heart rate of conscious 3-month-old, NTG and TG mice were determined as previously described (22) . Each measurement was performed in triplicate and was repeated on two separate days. The values obtained on the second day of measurement were presented as means ± SE, although there was no difference in the systolic blood pressure or heart rate obtained on the two days (P>0.1, paired t-test).
RESULTS
Functional features of the contractile response mediated by the native cardiac myocyte P2 receptor
There are seven P2X receptors, P2X [1] [2] [3] [4] [5] [6] [7] , cloned to date (6, 7). The P2X receptors are ligand-gated ion channels capable of permeating Na
. Of the seven P2X receptors, the mRNA's for P2X 1, 4, 5, 6 receptors are expressed in the heart (7, (23) (24) (25) . Features of the increased contractility mediated by the native P2 receptor in the cardiac cell were characterized here. The objective was to compare the pharmacological features of the native cardiac P2 receptor with those of the cloned P2 receptors. Among the P2X receptors, the P2X 4 receptor appeared to be important in mediating the increased cardiac contractility by the P2 agonist. First, the 2-meSATP-stimulated increase in mouse cardiac cell contractile amplitude was insensitive to blockade by the P2 receptor antagonist suramin. 2-meSATP can activate all P2X receptor subtypes and have weak or no agonist activity at any of the cloned P2Y receptors (7, 8) . Thus, 2-meSATP was used as a P2X receptor-selective agonist in all current studies. The percentage of increase in response to 2-meSATP was 42 ± 7% (± SE, n=33 cells from 10 mice), whereas the percentage of increase in the presence of 2-meSATP and suramin was 59 ± 7% (n=12 cells from 7 mice). Similar data were obtained in the rat cardiac cell (not shown). Insensitivity of the native cardiac P2 response to P2 receptor antagonist is similar to that of the cloned P2X 4 receptor-mediated response to the same antagonist (24, 26) . Of the seven cloned P2X receptors, insensitivity to blockade by antagonist is characteristic of the P2X 4 and P2X 6 receptors only (24, 26) . Second, the P2 receptor agonist α,β-methyleneATP is a weak agonist at stimulating the contractile amplitude in both mouse (percentage of stimulation of 13 ± 2%, n=14 myocytes from 6 mice; Fig. 1A ) and rat cardiac cells (15) , similar to its weak agonist activity at the cloned mouse or rat P2X 4 receptor. Of the seven cloned P2X receptors, α,β-methyleneATP is a weak agonist at the P2X 4 , P2X 5 , or P2X 6 receptors. P2X 5 receptor-mediated current is much smaller than that induced by other P2X receptors (25, 26) , which argues against the P2X 5 receptor as a mediator of the relatively large positive inotropic response of the cardiac myocyte to 2-meSATP. Further, the current-mediated by P2X 5 receptor can be blocked effectively by the P2 antagonist suramin, providing evidence against an important role of the P2X 5 receptor. Third, P2X 4 receptors are expressed in isolated cardiac cells, as determined by immunoblotting of homogenates from mouse (Fig. 1B) and rat (not shown) heart cells.
Cardiac transgenic expression of the P2X 4 receptor: characterization of the α-MyHC P2X 4 
receptor transgenic mouse
To elucidate the role of ATP and its receptor in the heart, TG mouse with cardiac-specific overexpression of the human P2X 4 receptor was developed, and both intact heart and isolated cardiac cell functional studies were carried out. The human P2X 4 receptor was targeted to the heart by using the α-MyHC promoter. TG mice were generated in the B6SJL/F1 background, and mice containing the transgene were identified by PCR by using an upstream primer 5'-GTCGACTGACTAACTAGAAGCT-3' complementary to the α-MyHC linker region of the α-MyHC vector, and a downstream primer 5'-CTGAGCTGGTATCACATAATCC-3' complementary to human P2X 4 receptor (position 288-310) ( Fig. 2A) . Presence of the transgene was confirmed by Southern blotting of the genomic DNA ( Fig. 2A) . Overexpression of the P2X 4 receptor in the TG mouse was demonstrated by immunohistochemistry of the isolated cardiac cell (Fig. 2B) , and the intact heart section ( Fig. 2C) as well as by immunoblotting of homogenates from both isolated cardiac cells and intact hearts (not shown).
Cardiac transgenic expression of the P2X 4 receptor showed the gain of an essential biological function, that of cardiac contractility TG overexpression of the P2X 4 receptor resulted in an enhanced basal cardiac performance. Compared with the NTG animal, the P2X 4 receptor mouse exhibited a higher basal level of cardiac output, contractility (+dP/dt), relaxation (-dP/dt) (Fig. 3) , and LVDP (not shown) (P<0.001, Student's t-test). The LVDP in the TG animal was 108±3 mm Hg (n=28, ±SE) and was significantly greater than that in the NTG animal (88±2.4 mm Hg, n=26, ±SE) (P<0.0001, Student's t-test). The peak left ventricular systolic pressure was also significantly higher in the TG (101.6 ± 2.6 mm Hg) than in the NTG (86±3.4) animals (P<0.01, Student's t-test). There is no difference in the basal heart rate between the TG and the NTG animals (P>0.1, Student's ttest) using the working heart model preparation. The enhanced basal cardiac performance in the TG mouse is not associated with the development of cardiac hypertrophy or heart failure at up to six months of observation. Compared with the NTG animals, TG mice showed a greater increase in +dP/dt (Fig. 3C) and -dP/dt (not shown) in response to the maximal concentration of 2-meSATP tested (1 µM). The heart weight and heart weight-to-body weight ratio are similar in the TG and NTG mice as are the systolic blood pressure and heart rate obtained in conscious animals (Table 1a) . Hematoxylin and Eosin staining of the TG mouse heart was similar to that obtained in the NTG animal. Examination of the TG and NTG cardiac myocytes under light microscopy showed no apparent difference in the general appearance of the myofibrils. The lack of a difference in heart rate, systolic blood pressure, and heart weight and heart weight-to-body weight ratio further supports an absence of overt pathology in the P2X 4 receptor TG animal.
The mechanism that underlies the increased basal cardiac function was determined next. Specifically, the hypothesis is that the endogenous ATP activates the overexpressed P2X 4 receptor and causes an enhanced cardiac contractility in the intact heart. This hypothesis would predict that, with dissipation of the endogenous ATP, cardiac ventricular cells isolated from the P2X 4 receptor TG animal would show similar basal contractile function as cells isolated from the NTG heart. The present data show that this is indeed the case. The basal contractile function was determined by quantitating the amplitude of contraction and normalizing the amplitude to the resting cell length. In the chamber in which the contractile amplitude was measured, ATP was not detected in the agonist-free superfusing solution bathing either the NTG (n=8 cells from 4 mice) or the TG cardiac myocytes (n=9 cells from 3 mice). Superfusing with ATP (1 µM)-containing buffer showed a steady ATP concentration that measured ~1 µM during the continuous superfusion. If there were any ATP produced or accumulated in the superfusing media in the contractility chamber, they would have been detectable, as the sensitivity of luciferase assay for ATP was 0.1 nM. These data indicate an absence of the endogenous ATP under the condition in which the basal level of myocyte contractility was quantitated. The basal contractile amplitude, expressed as a percentage of resting cell length, was similar in both TG and NTG animals (Table 1b) . However, cardiac cells from P2X 4 receptor TG mice showed a threefold greater increase of myocyte contractility in response to the P2X agonist than cells from the NTG heart (Fig. 4) . In the NTG group, the percentage of stimulation of contractile amplitude in response to 2-meSATP (1 µM) was 40± 4.3% (± SE, n=51 cells from 16 mice). The percentage of stimulation in the TG group was 140 ± 16% (n=37 cardiac cells from 12 mice). Thus, the basal contractile function is similar in both the TG and the NTG cardiac cells.
DISCUSSION
Activation of the P2 purinergic receptor exerts a number of potentially important effects in the heart (for review, see 6, 7, 13, 27) . In cardiac cells, the endogenous ligand for the P2 receptor, ATP, stimulates a large increase in the cytosolic calcium transient and myocyte contractile amplitude (9) (10) (11) (12) (13) (14) (15) . Our recent study demonstrated that activation of the P2 receptor can also enhance cardiac contractility in the intact heart (15). In both rat and mouse hearts, the P2X receptor agonist 2-meSATP elicited a significant increase in the rate of contraction (+dP/dt) and relaxation (-dP/dt) as well as the cardiac output in both Langendorff and working heart models.
Although the P2X agonist-stimulated increase in cardiac contractility was significantly less than that caused by the beta-adrenergic agonist isoproterenol, the positive inotropic response of the P2X agonist was not accompanied by any significant chronotropic effect. This finding is in marked contrast to the significant positive chronotropic effect that is associated with the betaadrenergic agonist. Thus, P2X agonist-induced positive inotropic effect would not entail a raterelated increase in myocardial oxygen consumption. To elucidate the biological role of ATP in the heart and to help identify the receptor that mediates its positive contractile response, we used two approaches in the current study. The first approach characterized the functional features of the increase in cardiac contractility mediated by the native myocyte P2 receptor and compared them with those of the cloned P2X receptor subtypes (7, 8, (23) (24) (25) (26) . In the second approach, cardiac TG expression of the P2X 4 receptor was developed and both intact heart and isolated cardiac cell functional studies were carried out.
The importance of the P2X 4 receptor in mediating the contractile effect of the P2X agonist 2-meSATP was supported by its expression in the cardiac cell, by the insensitivity of the native myocyte P2 response to inhibition by known P2 antagonists such as suramin or pyridoxalphosphate-6-azophenyl-2',4'-disulphonic acid tetrasodium (data not shown), and by the relative inability of α,β-meATP to stimulate a positive inotropic response. The pharmacological features of this native cardiac P2 response are conserved in both the rat and the mouse cardiac cells and are similar to the features of cloned rat and mouse P2X 4 receptor. If the P2X 4 receptor is important in mediating the positive contractile effect of ATP, one may anticipate that cardiac TG overexpression of the receptor should result in a gain of its contractile function in the heart. The present data showed that this is indeed the case. Thus, TG mice overexpressing the P2X 4 receptor have an elevated basal level of cardiac contractility and performance. All of the cardiac parameters measured, such as LVDP and cardiac output and the indices of contractility and relaxation (±dP/dt), showed a greater basal level in the TG mouse. The TG heart also showed a greater increase of cardiac contractility in response to the P2X receptor agonist 2-meSATP than did the NTG heart, consistent with overexpression of a functional P2X 4 receptor with consequent increase in the receptor-mediated cardiac contractility.
The increased basal cardiac contractility in the TG mouse is likely due to an enhanced activation of the P2X 4 receptor owing to a combination of receptor overexpression and the presence of endogenous ATP. Thus, with dissociation of the cardiac cell and dissipation of the endogenous ATP in the superfusion chamber in which the individual cell's contractile amplitude was measured, the contractile amplitude of TG mouse cardiac cell was similar to that of the NTG cell. This similarity was observed whether the contractile amplitude was compared directly or whether the amplitude was first normalized to its resting cell length. Although it is possible that the perfused TG heart releases an agent that stimulates contractility, the simplest explanation is that the enhanced basal cardiac performance in the intact TG heart is due to activation of the overexpressed P2X 4 receptor by the endogenous ATP.
The only other P2X receptor subtype that has similar features in the response to P2 agonists and antagonists as the native cardiac P2 receptor is the P2X 6 receptor. However, cloned P2X 6 receptor cannot be expressed easily into a functional receptor in a number of heterologous cells, including even the Xenopus oocytes (23, 26, 28) . Although mRNA for P2X 6 receptor is detected in the intact heart, whether it is expressed as a functional protein and whether it is localized on the cardiac cell are unknown. The cloned P2X 6 receptor is very poorly expressed in heterologous systems, with either very limited expression of a functional receptor/channel or none (25, 26) . Such data have been interpreted to indicate that the P2X 6 receptor does not form a homomeric receptor in the native tissue. The potential biological function of P2X 6 receptor remains to be determined. Overall, the present study provides strong evidence for the concept that P2X 4 receptor plays an important role in mediating the contractile effect of ATP in the heart. Cardiac TG expression of the P2X 4 receptor resulted in the gain of an essential biological function, that of an enhanced cardiac performance. This finding suggests a novel physiologic role of the P2X 4 receptor, that of stimulating the cardiac contractility. Systolic blood pressure 122 ± 3 (n=25) 116 ± 3 (n=24) (mm Hg)
Heart rate 670 ± 13 655 ± 13 (bpm) (A) The heart weight (mg) and the heart weight/body weight ratio (mg/gm) were determined. Data were shown as means ± S.E. from 15 three-month non-transgenic and 16 age-matched transgenic mice. The systolic blood pressure and heart rate of conscious three-month old non-transgenic and transgenic mice were determined as described in METHODS. The systolic blood pressure and heart rate were similar in both groups of mice (P>0.1, Student's t test). (B) The contraction amplitude, measured in µm or as a fraction of the resting cell length, was similar in P2X 4 receptor transgenic and nontransgenic mouse cardiac cells (P>0.1, t test) (n = 37 cells from 12 transgenic mice; n=51 cells from 16 non-transgenic mice). The basal contractile amplitude was then normalized to the resting cell length as % resting cell length to account for variability of the length of each cardiac cell. The basal contractile amplitude, the resting cell length (data not shown), and the % resting cell length were similar in both types of animals (P>0.1, Student's t test). Data were shown as means ± S.E. nontransgenic B6SJL/F1 mice according to previously described methods (16) . Adult rat cardiac cells were isolated according to previously described methods (15) , except that liberase was used as the digesting enzyme at a concentration of 0.1 mg/ml. A) Contractile amplitude of individual mouse cardiac cells from nontransgenic B6SJL/F1 mice was quantitated by using an optical video motion detection system as described in Materials and Methods. The contractility tracing was representative of 14 cells from 6 mice. B) Isolated myocytes were solublized in SDS/PAGE sample buffer, and 50 µg of solublized proteins resolved by 10% SDS/PAGE, transferred to Nitrocellulose membrane (Schleicher & Schuell), followed by probing with rabbit polyclonal antibody directed against a unique c-terminus sequence of the rat P2X 4 receptor. The same antibody incubated with its peptide antigen was used as negative control. Similar results were obtained in four independent experiments. Immunohistochemistry of isolated cardiac cells (B) and of intact heart sections (C) of transgenic and nontransgenic mice was performed as described in Materials and Methods. In another study, paraffin-embedded heart sections from both transgenic and nontransgenic mice were subjected to Hematoxylin & Eosin staining (C). All data are representative of those obtained in six transgenic and six nontransgenic mice. such as left ventricular developed pressure, cardiac output, rate of contraction (the first derivative of rate of contraction over time), and rate of relaxation (first derivative of rate of relaxation over time), were quantitated by using the working heart model as described in Materials and Methods. Data points under each basal condition were summarized as mean ± SE from 28 transgenic and 26 nontransgenic animals, and the statistical differences were analyzed by Student's t-test (unpaired). The basal level of cardiac output (A) was significantly greater, as was the basal level of ±dP/dt (B), in the P2X 4 receptor transgenic mouse than in the nontransgenic animal (P<0.001, Student's t-test). C) The increase in +dP/dt and -dP/dt in response to 2-meSATP was also greater in TG than in NTG animals (P<0.05, Student's t-test). Data were mean ± SE of seven mice from each group. 
